Saturday 17 October 2026
Export EOCN’s income statement to Excel — free account
Eocene Ltd.
EOCN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.3% and free cash flow fell 67.7%, each against the same quarter a year earlier.
2.85
0.20
−6.56%
Follow EOCN
Eocene Ltd. (EOCN) P/E ratio
Eocene Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2018 | 0.0× | — |
| Sep 2018 | 0.0× | — |
| Jun 2018 | 0.0× | — |
| Mar 2018 | 0.0× | — |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| EOCN Eocene Ltd. | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)